RARE logo

RARE

Profile

Full Name

Ultragenyx Pharmaceutical Inc.

Ticker Symbol

RARE

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

January 31, 2014

Indexes

Not included

Website

http://www.ultragenyx.com

Employees

1294

Key Details

Price

$38.09(+1.20%)

Market cap

$3.52B(Mid cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$560.23M(+29.01% YoY)

Annual EPS

-$6.29(+23.76% YoY)

PE ratio

-

Next earnings date

May 2, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$38.09
RARE price is $38.09

30-Day Relative Volume

0.62
RARE 30-day relative volume is 0.62

Price Performance

Price Most recent change

+1.2%
RARE price was up +1.2% on Apr 25, 2025

Price YTD change

-9.46%
RARE price is down -9.46% since January 1st

Price 1-year change

-13.14%
RARE price is down -13.14% year-on-year

Price 3-year change

-49.66%
RARE price is down -49.66% over the past 3 years

Price Range

Price All-time high

$179.65
RARE price is currently -78.80% below its historical high of $179.65

Price 3-year low

$29.59
RARE price is currently +28.73% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$3.52B
RARE market capitalization is $3.52 billion

Market cap 3-year change

-33.31%
RARE market capitalization is down -33.31% over the past 3 years

Market cap All-time high

$11.74B
RARE market capitalization is currently -69.98% below its historical high of $11.74 billion

Market cap sector rank

87.74%
RARE market capitalization is higher than 87.74% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+11.31%
RARE shares outstanding is up +11.31% year-on-year

Shares Outstanding 3-Year Change

+32.47%
RARE shares outstanding is up +32.47% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

0.82
RARE beta is 0.82

200-day SMA

$46.55
RARE price is currently -18.18% below its 200-day simple moving average

50-day SMA

$38.37
RARE price is currently -0.72% below its 50-day simple moving average

RSI

57.21
RARE 14-day relative strength index is 57.21

Volume

0.62
RARE 30-day relative volume is 0.62

ATR

$1.61
RARE average true range is $1.61

10-day Historical Volatility

24.22%
RARE 10-day historical volatility is 24.22%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$560.23M
RARE annual revenue is $560.23 million

Revenue Analysts estimate

$655.81M
RARE annual revenue is currently -14.57% lower than the consensus analysts' forecast

Revenue 1-year change

+29.01%
RARE annual revenue is up +29.01% year-on-year

Revenue Sector rank

74.52%
RARE annual revenue is higher than 74.52% of companies in Healthcare sector

EPS

EPS

-$6.29
RARE annual earnings per share is -$6.29

EPS Analysts estimate

-$5.43
RARE annual earnings per share is currently +15.84% higher than the consensus analysts' forecast

EPS 1-year change

+23.76%
RARE annual earnings per share is up +23.76% year-on-year

EPS Sector rank

16.11%
RARE annual earnings per share is higher than 16.11% of companies in Healthcare sector

Profit

Gross profit

$483.50M
RARE annual gross profit is $483.50 million

Gross margin

86.30%
RARE annual gross profit margin is 86.30%

Operating profit

-$535.97M
RARE annual operating income is -$535.97 million

Operating margin

-95.67%
RARE annual operating profit margin is -95.67%

Net income

-$569.18M
RARE annual net profit is -$569.18 million

Net margin

-101.60%
RARE annual net profit margin is -101.60%

Expenses

Total expenses

$1.10B
RARE annual total expenses is $1.10 billion

Operating expenses

$1.02B
RARE annual total operating expenses is $1.02 billion

Cost of goods sold

$76.73M
RARE annual cost of goods sold is $76.73 million

Selling, general & administrative expenses

$321.61M
RARE annual SGA is $321.61 million

Depreciation and amortization

$35.54M
RARE annual depreciation & amortization is $35.54 million

Interest expense

$63.04M
RARE annual interest expense is $63.04 million

Income tax

$1.60M
RARE annual income tax is $1.60 million

EBIT & EBITDA

EBIT

-$504.55M
RARE annual earnings before interest & taxes is -$504.55 million

EBITDA

-$504.55M
RARE annual EBITDA is -$504.55 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$1.50B
RARE annual total assets is $1.50 billion

Non current assets

$686.33M
RARE annual long term assets is $686.33 million

Current assets

$745.03M
RARE annual total current assets is $745.03 million

Cash and cash equivalents

$173.73M
RARE annual cash & cash equivalents is $173.73 million

Accounts receivable

$121.80M
RARE annual accounts receivable is $121.80 million

Inventory

$45.01M
RARE annual inventory is $45.01 million

Liabilities

Total liabilities

$1.24B
RARE annual total liabilities is $1.24 billion

Long term liabilities

$897.01M
RARE annual total long term liabilities is $897.01 million

Current liabilities

$344.15M
RARE annual total current liabilities is $344.15 million

Accounts payable

$38.76M
RARE annual accounts payable is $38.76 million

Debt

Total debt

$40.34M
RARE annual total debt is $40.34 million

Total debt 1-year change

-6.56%
RARE annual total debt is down -6.56% year-on-year

Long term debt

$30.04M
RARE annual long term debt is $30.04 million

Short term debt

$10.30M
RARE annual short term debt is $10.30 million

Equity & Capital

Shareholders equity

$255.30M
RARE annual stockholders equity is $255.30 million

Book value

$255.30M
RARE annual book value is $255.30 million

Retained earnings

-$3.96B
RARE annual retained earnings is -$3.96 billion

Working capital

$472.97M
RARE annual working capital is $472.97 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$414.19M
RARE annual cash flow from operations is -$414.19 million

Cash from operations 1-year change

+12.77%
RARE annual cash flow from operations is up +12.77% year-on-year

Cash from investing

-$17.77M
RARE annual cash flow from investing activities is -$17.77 million

Cash from investing 1-year change

-110.58%
RARE annual cash flow from investing activities is down -110.58% year-on-year

Cash from financing

$399.24M
RARE annual cash flow from financing activities is $399.24 million

Cash from financing 1-year change

+2.86%
RARE annual cash flow from financing activities is up +2.86% year-on-year

CAPEX

CAPEX

$19.99M
RARE annual capital expenditures is $19.99 million

CAPEX 1-year change

-57.25%
RARE annual capital expenditures is down -57.25% year-on-year

Free Cash Flow

Free cash flow

-$434.18M
RARE annual free cash flow is -$434.18 million

Free cash flow 1-year change

+16.76%
RARE annual free cash flow is up +16.76% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

86.30%
RARE annual gross profit margin is 86.30%

Operating margin

-95.67%
RARE annual operating profit margin is -95.67%

Net margin

-101.60%
RARE annual net profit margin is -101.60%

ROA & ROE

ROA

-38.02%
RARE annual return on assets is -38.02%

ROE

-211.71%
RARE annual return on equity is -211.71%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
RARE price to earnings ratio value is unknown

PE ratio Sector rank

-
RARE price to earnings ratio is unknown

PB Ratio

PB ratio

13.80
RARE price to book ratio is 13.80

PB ratio Sector rank

94.77%
RARE price to book ratio is higher than 94.77% of companies in Healthcare sector

PS Ratio

PS ratio

6.29
RARE price to sales ratio is 6.29

PS ratio Sector rank

69.87%
RARE price to sales ratio is higher than 69.87% of companies in Healthcare sector

Enterprise value

Enterprise value

$3.39B
RARE enterprise value is $3.39 billion

Enterprise value Sector rank

86.07%
RARE enterprise value is higher than 86.07% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-7.09
RARE EV/EBITDA is -7.09

EV/EBITDA Sector rank

15.83%
RARE EV/EBITDA is higher than 15.83% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

2.37
RARE annual current ratio is 2.37

Quick ratio

2.03
RARE annual quick ratio is 2.03

Leverage

Debt to equity

0.00
RARE annual debt to equity ratio is 0.00

Interest coverage ratio

-8.00
RARE annual interest coverage ratio is -8.00

Risk & Stability

Piotroski F-Score

3
RARE piotroski f-score is 3

Altman Z-Score

-2.34
RARE altman z-score is -2.34

Analyst ratings

Recent major analysts updates

Oct 22, 24 Cantor Fitzgerald
Overweight
Oct 21, 24 TD Cowen
Buy
Oct 1, 24 Cantor Fitzgerald
Overweight
Sep 26, 24 RBC Capital
Outperform
Sep 20, 24 Cantor Fitzgerald
Overweight
Sep 16, 24 Cantor Fitzgerald
Overweight
Aug 5, 24 Barclays
Overweight
Aug 2, 24 Wells Fargo
Overweight
Aug 2, 24 Wedbush
Neutral
Aug 2, 24 Goldman Sachs
Buy

Institutional Ownership

Similar stocks

ACLX logo
Arcellx (ACLX)
ZLAB logo
Zai Lab Limited (ZLAB)
PRGO logo
Perrigo (PRGO)
ALHC logo
Alignment Healthcare (ALHC)
SLNO logo
Soleno Therapeutics (SLNO)
SWTX logo
SpringWorks Therapeutics (SWTX)
RNA logo
Avidity Biosciences (RNA)
IRTC logo
iRhythm Technologies (IRTC)
ICUI logo
ICU Medical (ICUI)
  • What is the ticker symbol for Ultragenyx Pharmaceutical?
  • Does Ultragenyx Pharmaceutical pay dividends?
  • What sector is Ultragenyx Pharmaceutical in?
  • What industry is Ultragenyx Pharmaceutical in?
  • What country is Ultragenyx Pharmaceutical based in?
  • When did Ultragenyx Pharmaceutical go public?
  • Is Ultragenyx Pharmaceutical in the S&P 500?
  • Is Ultragenyx Pharmaceutical in the NASDAQ 100?
  • Is Ultragenyx Pharmaceutical in the Dow Jones?
  • When was Ultragenyx Pharmaceutical's last earnings report?
  • When does Ultragenyx Pharmaceutical report earnings?
  • Should I buy Ultragenyx Pharmaceutical stock now?

What is the ticker symbol for Ultragenyx Pharmaceutical?

The ticker symbol for Ultragenyx Pharmaceutical is NASDAQ:RARE

Does Ultragenyx Pharmaceutical pay dividends?

No, Ultragenyx Pharmaceutical does not pay dividends

What sector is Ultragenyx Pharmaceutical in?

Ultragenyx Pharmaceutical is in the Healthcare sector

What industry is Ultragenyx Pharmaceutical in?

Ultragenyx Pharmaceutical is in the Biotechnology industry

What country is Ultragenyx Pharmaceutical based in?

Ultragenyx Pharmaceutical is headquartered in United States

When did Ultragenyx Pharmaceutical go public?

Ultragenyx Pharmaceutical's initial public offering (IPO) was on January 31, 2014

Is Ultragenyx Pharmaceutical in the S&P 500?

No, Ultragenyx Pharmaceutical is not included in the S&P 500 index

Is Ultragenyx Pharmaceutical in the NASDAQ 100?

No, Ultragenyx Pharmaceutical is not included in the NASDAQ 100 index

Is Ultragenyx Pharmaceutical in the Dow Jones?

No, Ultragenyx Pharmaceutical is not included in the Dow Jones index

When was Ultragenyx Pharmaceutical's last earnings report?

Ultragenyx Pharmaceutical's most recent earnings report was on Feb 13, 2025

When does Ultragenyx Pharmaceutical report earnings?

The next expected earnings date for Ultragenyx Pharmaceutical is May 2, 2025

Should I buy Ultragenyx Pharmaceutical stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page